BOSTON, May 29, 2026
Ratio Therapeutics has expanded its manufacturing collaboration with PharmaLogic Holdings Corp. to support the clinical development and future commercialization of [Ac-225]RTX-2358, the company’s lead fibroblast activation protein-alpha (FAP)-targeted radiotherapeutic candidate. The enhanced agreement increases manufacturing capacity, introduces additional production redundancy, and strengthens commercial readiness as the investigational therapy advances through clinical development for patients with difficult-to-treat solid tumors.
Expanded Manufacturing Capacity Supports Clinical Growth
Ratio Therapeutics and PharmaLogic are broadening their partnership by adding manufacturing operations at PharmaLogic’s Idaho Falls therapeutics facility, significantly increasing production capabilities for [Ac-225]RTX-2358. The collaboration also includes process optimization initiatives aimed at enabling larger-scale multi-dose batch manufacturing. These enhancements are designed to ensure a reliable supply of the radiopharmaceutical for ongoing and future clinical studies, including potential registrational and late-stage trials. As demand for targeted radiotherapies continues to grow, scalable manufacturing infrastructure has become increasingly important for supporting development timelines and eventual commercial distribution.
RTX-2358 Advances Novel FAP-Targeted Radiopharmaceutical Approach
[Ac-225]RTX-2358 is an investigational Actinium-225-based alpha-emitting radiotherapeutic designed to target tumors expressing fibroblast activation protein-alpha (FAP). The therapy utilizes a trifunctional small-molecule platform engineered to optimize plasma clearance, improve binding affinity, and prolong tumor retention while delivering the potent alpha-particle emitting isotope directly to cancer cells. This targeted approach is intended to maximize anti-tumor activity while minimizing exposure to healthy tissues. The candidate represents one of Ratio’s leading programs focused on advancing next-generation precision radiopharmaceuticals for the treatment of solid tumors.
Advertisement
ATLAS Trial Evaluates Therapy in Advanced Soft Tissue Sarcoma
The investigational therapy is currently being evaluated in the ongoing Phase 1/2 ATLAS (Actinium Therapy for Late-stage Aggressive Sarcomas) trial, which is enrolling patients with relapsed or refractory soft tissue sarcoma. The open-label study is designed to assess safety, tolerability, biodistribution, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of [Ac-225]RTX-2358. The Phase 1 portion uses a modified dose-escalation design to determine the maximum tolerated dose and establish a recommended Phase 2 dose, while the expansion phase is expected to enroll up to 50 patients to further evaluate efficacy and safety. By strengthening manufacturing capabilities now, Ratio aims to support uninterrupted clinical development and prepare for future regulatory and commercial milestones.
Partnership Strengthens Commercialization Readiness
According to company executives, the expanded collaboration reflects the growing importance of reliable, scalable manufacturing for radiopharmaceutical therapies, particularly those utilizing Actinium-225, a highly sought-after radioisotope in targeted cancer treatment. PharmaLogic, which operates more than 45 facilities across North America and Europe, brings extensive expertise in the development, manufacturing, and distribution of diagnostic and therapeutic radiopharmaceuticals. The partnership is expected to provide the production capacity, operational redundancy, and quality infrastructure required to advance RTX-2358 toward potential commercialization. The agreement also reinforces both companies’ commitment to accelerating innovation in precision oncology and improving treatment options for patients with aggressive cancers.
Source: Ratio Therapeutics, PharmaLogic press release
